FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

BridgeBio Pharma Sells Review Voucher for $110 Million

BridgeBio Pharma sells for $110 million its priority review voucher that was awarded last year when FDA approved Nulibry (fosdenopterin) for an ultra-...

Human Drugs

Inspection Findings Sideline UCB Psoriasis Drug

FDA sends UCB a complete response letter on its BLA for psoriasis-treating bimekizumab, citing deficiencies from a recent preapproval inspection as th...

Human Drugs

Scathing FDA-483 Hits Sun Pharma Over GMPs

A just-released, scathing (XXX INSERT XXX)23-page Form FDA-483 cites 10 GMP deficiencies at Sun Pharmaceutical Industries Halol manufacturing facility...

Human Drugs

Lilly Once-weekly Diabetes Injection Approved

FDA approves an Eli Lilly NDA for Mounjaro (tirzepatide), a once-weekly injection to improve blood sugar control in adults with Type 2 diabetes, as an...

Medical Devices

New BD COR Molecular Diagnostic Platform Cleared

FDA clears a BD (Becton, Dickinson) 510(k) for its new automated, high-throughput infectious disease molecular diagnostics platform, BD COR.

Medical Devices

Medtronic Onyx Frontier Drug-eluting Stent OKd

FDA approves a Medtronic PMA for the Onyx Frontier drug-eluting stent, indicated for treating patients with coronary artery disease.

Medical Devices

QSR Proposed Revisions Will Advance Harmonization: Post

Pharmatech Associates managing director Stephanie Gaulding discusses the effects of an FDA proposed revision to the medical device Quality System Regu...

Human Drugs

BMS Updates Psoriasis Drug Safety/Efficacy

Bristol Myers Squibb provides two-year results from its POETYK PSO long-term extension trial of deucravacitinib in adult patients with moderate to sev...

Federal Register

Meeting on User Fee Financial Transparency

Federal Register notice: FDA announces a 6/7 public meeting entitled Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Bios...

Human Drugs

Appeals Court Decision Hurts Drug Research Incentives: FDA

FDA says an appeals court decision in a case involving orphan drug exclusivity is likely to slow research and innovation into drugs for rare diseases.